GSA Capital Partners’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

GSA Capital Partners’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-47,595	Closed	-$75K	–	2026
2022 Q3	$75K	Buy	47,595 +26,074	+121%	+$59.1K	0.01%	1397
2022 Q2	$43K	Sell	21,521 -299,608	-93%	-$518K	0.01%	1300
2022 Q1	$748K	Buy	321,129 +286,428	+825%	+$893K	0.1%	308
2021 Q4	$161K	Sell	34,701 -662	-2%	-$4.11K	0.02%	1261
2021 Q3	$270K	Buy	+35,363	New	+$300K	0.03%	1085
2021 Q2	–	Sell	-25,808	Closed	-$213K	–	1697
2021 Q1	$213K	Buy	25,808 +7,390	+40%	+$78K	0.04%	865
2020 Q4	$126K	Buy	+18,418	New	+$148K	0.02%	1073
2018 Q3	–	Sell	-77,895	Closed	-$561K	–	1990
2018 Q2	$561K	Sell	77,895 -157,600	-67%	-$1.07M	0.03%	1098
2018 Q1	$1.21M	Buy	+235,495	New	+$1.68M	0.06%	535
2017 Q1	–	Sell	-17,019	Closed	-$83K	–	2063
2016 Q4	$83K	Buy	+17,019	New	+$102K	0.01%	1684
2016 Q1	–	Sell	-11,933	Closed	-$104K	–	1983
2015 Q4	$104K	Sell	11,933 -100,134	-89%	-$845K	0.01%	1736
2015 Q3	$940K	Buy	+112,067	New	+$1.79M	0.05%	685
2015 Q2	–	Sell	-25,889	Closed	-$299K	–	2247
2015 Q1	$299K	Buy	+25,889	New	+$300K	0.01%	1711

Other funds holding SRNE

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BRF

B. Riley Financial Los Angeles, California $434M AUM 751.56% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

GSA Capital Partners's SRNE Position: Q4 2022 in Review

GSA Capital Partners sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2022, closing a stake of 47,595 shares — an estimated $75K sold.

GSA Capital Partners first reported a position in SRNE in Q1 2015 and held it in 13 quarters. The position peaked at $1.21M in Q1 2018. 221 funds tracked by Wall St. Rank hold SRNE as of Q4 2022.

GSA Capital Partners reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
GSA Capital Partners sold 47,595 Sorrento Therapeutics, Inc. shares in Q4 2022, an estimated $75K.
GSA Capital Partners first reported a position in Sorrento Therapeutics, Inc. in Q1 2015 and held it in 13 quarters.
GSA Capital Partners's Sorrento Therapeutics, Inc. position peaked at $1.21M in Q1 2018.
221 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2022.

Based on GSA Capital Partners's 13F filing for Q4 2022, filed 13 Feb 2023.